Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538 (nivolumab) for recurrent/progressive meningioma
jRCT2031190074Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in meningioma, sponsored by Ono Pharmaceutical. Primary endpoint: Response rate by iRANO (meningioma) - independent review. Started Sep 2019; status: completed.
02
Drugs
03
Conditions
meningioma
Beyond the preview
Go deeper on jRCT2031190074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190074.